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1. Introduction 
The main task of the immune system is to defend the body against pathogens. The ability of 
the immune system to recognize and eliminate cancer cells is the basis for cancer 
immunotherapy. There is ample evidence of how important role plays the immune system 
to fight cancer: (i) spontaneous remission in patients with certain cancers; (ii) the presence of 
specific cytotoxic T lymphocytes in the environment of the tumor or regional lymph nodes, 
(iii) the presence of monocytes, lymphocytes and plasma cells infiltrating the tumor, (iv) 
increased incidence of some malignancies in immunosuppressed patients, (v) documented 
remissions of the disease after use of immunomodulators. Better understanding of the 
molecular and cellular mechanisms that control the immune system has enabled the 
development of many innovative and promising therapeutic strategies that modulate the 
immune response. It seems that in the next 5 to 10 years past surgery, radiotherapy and 
chemotherapy, immunotherapy will find a permanent position in the treatment of cancer 
modalities. 
2. Anti-tumour immune response 
Cancerogenesis is closely associated with non-lethal damage of genetic material. Such 
genetic damage (mutations) can stem from environmental factors, e.g. chemical, radioactive 
or viral, or can be hereditary. Neoplastic transformation occurs due to accumulation of 
mutations, predominantly in two gene classes: protooncogenes and suppressor genes. 
Mutated protooncogenes, termed oncogenes, promote autonomous cell proliferation. 
Proteins produced by the oncogenes transmit signals to cell nucleus and induce cell 
division. In contrast, mutated suppressor genes become inactivated and their protein 
products, deprived of their suppression properties, are not capable of controlling incorrect 
proliferation. Mutations in apoptosis-regulation genes via the synthesis of improper 
proteins develop mechanisms preventing programmed cell death. 
Burnet’s and Thomas’ immune surveillance theory assumes that newly formed neoplastic 
cells are continually monitored by the human immune system which recognises and 
eliminates them. At some point, however, tumour cells escape immune surveillance, what 
may result in fully-fledged tumours. During the last twenty years, a number of mechanisms 
which enable tumour cells to evade effector immune mechanisms have been identified. They 
include: 
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- reduced expression/absence of expression of major histocompatibility complex 
antigens class I and II – (MHC I and II) (Resifo et al., 1993; Garrido et al., 1993; Ward et 
al., 1990) 
- loss of tumour antigens (Knurth et al., 1989; Uyttenhove et al., 1983; Ward et al., 1989) 
- improper intracellular antigen processing to prepare antigens for presentation (defects 
in proteosome function or adenosine-tri-phosphatate (ATP) dependent proteins 
transporting TAP peptides (Selinger et al., 1998) 
- reduction/loss of costimulatory signals of e.g. B7 molecules on the surface of tumour 
cells 
- suppressed expression of adhesion molecules 
- inhibited expression of the Fas receptor and/or Fas ligand resulting in the apoptosis of 
cytotoxic T lymphocytes (CTL) and/or natural killer (NK) cells (Strand et al., 1996; 
Hahne et al., 1996; Walker et al., 1997) 
- synthesis and secretion of immunosuppressive factors, e.g. interleukin (IL)10, TGF-beta, 
prostaglandine E2  suppressing immune response (Boon et al., 1995; Schmidt-Wolf et al., 
1995) 
- expression of TRIAL (TNF-related apoptosis inducing ligand) on the tumour cell 
surface leading to T lymphocyte apoptosis (Baker et al., 1998) 
- prolonged stimulation of specific T cells resulting in clonal exhaustion or AICD 
(activation-induced cell death) (Overwijk et al., 2001) 
The term “cancer immunosurveillance” is no longer sufficient to precisely describe the 
difficult interactions that arise among a developing tumor and the immune system of the 
host. It was believed that cancer immunosurveillance was protecting the host by the 
adaptive immune system in the early phase of cell transformation. Dunn and coworkers 
described that not only the adaptive but also innate immune system plays a role in the 
process and serve not only to defend the host from tumor development but also to sculpt, or 
edit, the immunogenicity of tumors that may finally form. The authors use a wider term -  
“cancer immunoediting” to more suitably stress the double roles of immunity in not only 
preventing but also shaping neoplastic disease. According to this theory cancer 
immunoediting comprises of three phases: elimination, equilibrium and escape.  
Elimination phase is based on the original concept of cancer immunosurveillance. If during 
this phase the developing tumor can be successfully eliminated the immunoediting process 
is completed without progression to the subsequent phases. 
If the neoplasm circumvents the immune surveillance system, it may enter the next sub-
clinical stage, termed the equilibrium phase, in which tumour tries to establish itself and 
withstand the growing pressure exerted by the immune system. Although lymphocytes and 
the secreted IFN-gamma attack the tumour cell, its genetic instability and multiple 
mutations protect it against destruction. The equilibrium phase is a long-term process and 
may last for years. The next stage is the escape phase which can stem from the exhaustion or 
suppression of the immune system, reduced expression of type I MHC on neoplastic cells or 
decreased sensitivity to interferon (IFN) gamma. The equilibrium phase does not occur in 
non-immunogenic tumours and the modified cell automatically enters the escape phase. 
This clinical stage is associated with fast growth and progression of the tumour (Dunn et al., 
2002 & 2006).  
In tumours induced by viruses and chemical substances it has been found that tumour-
related antigens are immunogenic and trigger specific cellular and humoral responses. 
Cytotoxic cells, including CD8+ CTL, NK cells and CD4+ T helper cells, are presumed to 
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play a decisive role in the process. Cellular immune response also involves neutrophil 
granulocytes (Cavallo et al., 1992) and macrophages. Humoral response is executed by 
antibodies which are directed against tumour antigens produced by activated B 
lymphocytes – plasmocytes. The process leading to the lysis of tumour cells in this 
mechanism may comprise activation of the complement system or induction of ADCC 
(Antibody Dependent Cell-mediated Cytotoxicity). 
The role of different subpopulations of helper T lymphocytes (Th cells) has not been fully 
explored yet (Nishimura et al., 1999). Cytokines secreted by helper T cells activate humoral 
or cellular anti-tumour immune response. Depending on the profile of secreted cytokines, 
Th cells are divided into two sub-groups: Th1 producing IL-2, IFN-gamma and IL-12 
inducing cellular immune response; and Th2 secreting IL-4, IL-5, IL-6 and IL-10 which 
stimulate the humoral response and suppresses the cellular response (Swain et al., 1995). 
Moreover, the subpopulation of regulatory T cells CD4+/CD25+hihgFoxp3 may inhibit 
immune response by paracrinous secretion of immunosuppressive cytokines IL-10 and TGF-
beta. Th17 lymphocytes belong to the most recently described CD4+Th . A characteristic 
feature of these cells is the secretion of interleukin-17 but also IL-22, IL-26, IL-6, TNF-alfa. So 
far, no unequivocal influence of Th17 lymphocytes for the development of cancer has been 
described. It was shown that IL-17 may promote tumor cell growth by inducing tumor 
vascularization or enhancing inflammation. Meanwhile, a lot of data suggests the antitumor 
activity of Th17 cells. It therefore appears that Th17 cells may have different effects on tumor 
growth depending on its immunogenicity, clinical stage (different role in the early and late 
stages), as well as the origin of cancer and the influence of inflammation and angiogenesis in 
tumor microenvironment (Hus et al., 2010). 
Effective anti-tumour response elicited by the immune system consists of two phases, 
induction and effector. The induction phase is marked by stimulation of specific anti-
tumour response, while the effector phase involves a selective elimination of tumour cells. 
The following mechanisms are sequentially activated in the induction phase: 
1. Presentation of tumour antigens in the context of HLA (Human Leukocyte Antigens) 
class I to CD8+ lymphocytes, or HLA class II to CD4+ lymphocytes; 
2. Providing the costimulatory signal for T lymphocytes, e.g. binding of B7.1 molecules 
(CD80, CD86) with the CD28 receptor on the surface of T lymphocytes (Janeway et al., 
1994) 
3. Providing the proliferation signal for immune cells in the area of tumour antigen 
presentation (typically cytokines or growth factors) (Pardoll et al., 1995) 
Induction of immune response is initiated by antigen presentation by dendritic cells (DCs) 
(Banchereau et al., 1998). DCs phagocyte antigens from necrotic or apoptotic tumour cells 
and then migrate into regional lymph nodes, where they undergo maturation. In the lymph 
nodes, they present the antigen on their surface to T lymphocytes CD8+ (in the context of 
HLA I) and to T lymphocytes CD4+ (in the context of HLA II). This is where CD8+ and 
CD4+ CTLs are formed together with antibodies directed against specific tumour antigens.  
The stimulation of humoral response requires a presentation of tumour antigen by a B 
lymphocyte to the specific CD4+T lymphocyte. Direct lymphocyte interaction, as well as 
production of cytokines by CD4+, triggers transformation of the B lymphocyte into a plasma 
cell and secretion of antibodies. 
The effector phase of anti-tumour response may include the following cell destruction 
mechanisms by: 
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1. Specific activated CD8+ and CD4+ CTLs 
2. Activated NK cells 
3. Tumour-infiltrating granulocytes and macrophages 
4. Specific antibodies determining activation of the complement system or ADCC  
5. Inhibition of tumour neoangiogenesis by cytokines, such as IFN-gamma secreted by 
activated T lymphocytes (CD8+ and CD4+) into the tumour microenvironment. 
Absence of one or several components listed above makes it possible for tumour cells to 
escape immune surveillance, which leads to tumour progression. Mechanisms involved in 
the induction and effector phases of anti-tumour response which have been identified so far 
makes it possible to apply immunotherapy to restore the capacity to recognise and eliminate 
tumour cells in immune defence mechanisms (Nanda et al., 1995). 
3. Tumour immunotherapy 
Tumour immunotherapy is a treatment strategy based on intentional interference with the 
human immune system in order to enhance or modify the body's defence mechanisms 
against the developing tumour. Immune therapy can be divided into two major categories: 
passive and active. Within each category the therapy might be either specific or non-specific. 
3.1 Passive non-specific immunotherapy 
Passive non-specific immunotherapy involves transfer of factors or activated effector cells to 
elicit a non-specific activation of the immune system provoking anti-tumour response. 
Immunotherapeutic approaches may use e.g. cytokines or LAK (Lymphokine Activated 
Killers) cells.  
Cytokines are low molecular weight proteins which play a vital role in all phases of immune 
response, both humoral and cellular. In order to display biological activity, cytokine must 
target a specific receptor on imune cells (T and B lymphocytes, NK cells, 
monocytes/macrophages and granulocytes). Various cytokines may demonstrate an 
antagonistic, agonistic, additive or synergistic effects in biological processes. Known anti-
tumour effects of cytokines include (i) direct cytotoxic effect (TNF-sensitivity of cancer cells 
to cytotoxic effects of various biological or chemical factors (IFN-gamma, TNF-alpha), (ii) 
inhibition of tumour cells proliferation (IFN-alpha, IFN-gamma) and (iii) activation of NK 
cells (Granulocyte-Macrophate Colony-Stimulating Factor – GM-CSF, IL-2, IL-6). 
The first recombinant cytokine registered for clinical application was IFN-alpha which has 
been used in the treatment of hairy-cell leukaemia, chronic myeloid leukaemia, melanoma, 
Kaposi’s sarcoma, metastatic renal cell cancer and malignant lymphoma.  
Several randomised phase III trials evaluating IFN-alfa-2a and IFN-2b in low, medium and 
high dose have been conducted. Only in two of them statistically significant improvement of 
OS (overall survival) was observed. High dose IFN-alfa-2b (Intron®) has been approved by 
the U.S. FDA (Food and Drug Administration) based on the results of ECOG 1684 trial. Intron 
is indicated in patients after resection of high-risk melanoma (stage IIB and stage III). In the 
registration trial 287 patients after surgical removal of melanoma were randomised into two 
study arms:  INF-alfa-2b vs observation. At a median follow-up of 6.9 years, a statistically 
significant improvement in survival was demonstrated for the patients treated with IFN-
alfa-2b. However at 12,6 years of follow-up, OS was not significantly different between the 
two study groups, even though there was a significant benefit for relapse free survival 
(RFS). About 80% of patients developed grade 3 and 4 toxicity (Kirkwood et al., 1996). In 
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another phase III study (ECOG 1694) efficacy of high-dose IFN-alfa-2b was compared with 
an experimental vaccine GM2-KLH21. After 2 years of median follow-up the median RFS 
and OS were significantly longer in patients treated with IFN-alfa-2b (Kirkwood et al., 2000). 
Concerns raising the vaccine control group used in ECOG 1694 lead to initiation of another 
randomized phase III trial (EORTC 18961). The study which enrolled 1314 patients with 
stage II melanoma evaluated efficacy of GM2-KLH21 compared with observation. The trial 
was closed early by the data monitoring committee because of longer survival in the 
observation arm (Eggermont et al., 2008a). Recently (March 2011) pegylated-IFN-alfa-2b 
(Sylatron®) has been approved for the treatment of patients with melanoma with 
microscopic or gross nodal involvement after definitive surgical resection including 
complete lymphadenectomy. The approval was based on the results of EORTC 18991 trial 
published in Lancet in the year 2008. The study enrolled 1256 patients with resected stage III 
melanoma to either observation or pegylated-IFN-alfa-2b. The estimated median RFS was 
34.8 months (95% confidence interval (CI): 26.1, 47.4) and 25.5 months (95% CI: 19.6, 30.8) in 
the Sylatron and observation arms, respectively [hazard ratio (HR) 0.82 (95% CI: 0.71, 0.96); 
unstratified log-rank p = 0.011].  Unfortuntly, there was no difference in OS between the 
Sylatron and the observation arms [HR 0.98 (95% CI: 0.82, 1.16)]. The grade 3 and 4 adverse 
events were less frequent in patients treated with pegylated-IFN-alfa-2b than observed in 
subjects receiving IFN-alfa-2b in earlier trials (Eggermont et al., 2008b). 
Another cytokine registered in the USA for palliative treatment of renal cancer and 
melanoma is IL-2, however, it has recently been demonstrated that high doses of IL-2 
stimulate Treg lymphocytes, what in fact suppresses immune response (Ahmadzadeh et al., 
2006).  
IL-2 was approved by FDA in 1998 for the treatment of patients with metastatic melanoma. 
Overall objective response rates in patients treated with high dose IL-2 was 17% (Rosenberg 
et al., 1994a). In a highly selected patient population with metastatic melanoma (270 
patients) complete response (CR) was observed in 6% with median duration of response 
over 59 months. Partial response (PR) was seen in 10% of IL-2 treated patients. Disease did 
not progress in any patient responding for more than 30 months. Grade 3 and 4 toxicity was 
very frequent (Atkins et al., 1993 & 1994). In another trial 684 patients with metastatic 
melanoma received high-dose IL-2 either alone or in combination with a variety of 
melanoma vaccines. The overall objective response rates were highest in patients treated 
with gp100:209-217(210M) peptide vaccine (22%) compared to IL-2 (13%) alone (P=0.01) 
(Smith et al., 2008). Number of clinical trials evaluating the efficacy of biochemotherapy 
(combination of chemotherapy and biological agents) have been conducted. In a small phase 
III trial the investigators compared sequential CVD (dacarbazine, cisplatin, vinblastine) 
chemotherapy with IL-2 and interferon alfa with CVD alone. Patients treated with 
biochemotherapy responsed more frequently (48%) to the treatment than receiving 
chemotherapy alone (25%). The median OS was 11,9 months vs. 9,2 months for 
biochemotherapy and CVD alone respectively (Eton et al., 2002). In another similar phase III 
randomized trial (E3695) the observation seen in the previous study was not confirmed – no 
improvement in OS between both study arms (CVD + IL-2 + IFN-alfa-2b vs CVD) (Atkins et 
al., 2008). A recent meta-analysis of 18 trials involving 2621 patients with metastatic 
melanoma showed that biochemotherapy improves overall response rate without benefit of 
survival (Ives et al., 2007).    
At the American Society of Clinical Oncology (ASCO) 2010 annual meeting Lawson et al. 
presented results of a phase III trial (E4697) evaluating efficacy of GM-SCF in the adjuvant 
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treatment in patients with resected high risk melanoma (stage III and IV). Patients were 
injected with 250 µg of GM-CSF or placebo s.c. daily for 14 consecutive days in a 4 week 
intervals. The treatment duration was 1 year. Median disease free survival (DFS) of patients 
treated with GM-CSF was significantly longer than of patients receiving placebo – 11,8 vs. 
8,8 months (p=0,034). Median OS was 72,1 vs. 59,8 months respectively in the study arm 
evaluating GM-CSF and placebo, but the difference was not statistically significant 
(P=0,551). Toxicity was consistent with known effects of GM-CSF (Lawson et al., 2010). 
Another type of passive non-specific immunotherapy is the transfer of LAK cells. In this 
method, mononuclear cells are isolated from the blood of a patient, stimulated with IL-2 ex 
vivo and injected back with a simultaneous administration of high doses of IL-2 for 
continuous lymphocyte stimulation. LAK-based therapy was used by Rosenberg in a clinical 
trial of renal cancer and melanoma. It was found, however, that the therapeutic effect was 
rather achieved by IL-2, but not LAK cells, which is why further trials were discontinued 
(Rosenberg et al., 1985 & 1993). 
3.2 Passive specific immunotherapy 
Passive specific immunotherapy is a treatment method based on the administration of 
factors or effector cells targeting specific tumour cells. Examples include application of 
antibodies directed against antigens present on tumour cells or cell therapies using tumour-
infiltrating lymphocytes (TIL) which are isolated, cultured, activated and then transferred 
back into the patient. High expectations are currently held for the recently developed 
therapy based on modification of autologous lymphocytes isolated from PBLs (Peripheral 
Blood Lymphocytes) (Morgan et al., 2006). 
Passive immunotherapy employing antibodies was first described as far back as 100 years 
ago. However, it was not until the development of a viable technique of generating 
monoclonal antibodies (mAb) (Kohler et al., 1975) that the method found more extensive 
applications in tumour therapy. The dynamic development of genetic engineering 
techniques has enabled generation of humanised and human mAb (technology using 
transgenic mice – Xenomouse®) (Green, 1999) deprived to the maximum extent possible of 
toxic effects associated with the induction of HAMA (Human Anti Murine Antibody) 
reaction.  
Modified specific mAb used in immunotherapy act by binding directly to the tumour 
antigen, activate ADCC and CDC (Complement Dependent Cytotoxicity). Monoclonal 
antibodies can also block receptors on tumour cells, e.g. growth factor receptors. Antibodies 
conjugated with radioisotopes, cytostatics, enzymes, cytokines or toxins immediately 
destroy cells which they target.   
The first mAb registered by the FDA in 1997 was Rituximab (MabThera®) used in the 
treatment of patients with low malignancy B-cell non-Hodgkin lymphomas. To date there 
are several mAb (trastuzumab, cetuximab, panitumumab, bevacizumab, ibritumomab, 
tiuxetan, tositumomab, gemtuzumab, ozogamicin, alemtuzumab) approved for the 
treatment of various malignancies. Ipilimumab, anti-CTLA4 (Cytotoxic T-lymphocyte–
associated antigen 4) mAb has been recently registered for the treatment of metastatic 
melanoma (described in section: active non-specific immunotherapy).  
Angiogenesis is of profound importance in melanoma development (Streit et al., 2003). 
Malignant melanocytes excrete vascular endothelial growth factor (VEGF) and fibroblast 
growth factor (FGF) (Kurzen et al., 2003, Lacal et al., 2000, Lev et al., 2003 & 2004). The VEGF 
is the fundamental regulator of new vessels formation in the tumour and its expression is 
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related to poorer prognosis in melanoma patients (Ugurel et al., 2001). Bewacizumab is a 
mAb directed against VEGF. Its effectiveness has been proven in the treatment of colon and 
kidney cancer (Saltz et al., 2008, Melichar et al., 2008). In the treatment of advanced 
melanoma its efficacy was evaluated in combination with low dose interferon-alfa-2b in a 
phase II trial which did not show extension of survival in studied patients (Varker et al., 
2007). In another phase II trial enrolling 62 metastatic melanoma patients, the effectiveness 
of bewacizumab in combination with temozolomide was tested. Objective clinical responses 
were observed in 26% of patients, while 30% of the patients developed SD (stabilization 
disease) lasting for 1.5–7.5 months (median of 3 months) (Von Mos R et al., 2007). In a 
subsequent phase II trial with 214 randomized patients, the therapy with bevacizumab in 
combination with carboplatin and paklitaxel (first line treatment) improved effectiveness as 
the median OS was significantly longer (12.3 months) than in the control group (8.6 months) 
treated with chemotherapy alone. The toxicity of treatment was similar in both study arms 
(the number of grade 3-5 adverse events was 2% greater in the group treated with 
bevacizumab) (O’Day et al., 2009). At the ASCO 2009 annual meeting, preliminary results 
were presented on the effectiveness of treatment with bevacizumab in combination with 
nab-paklitaxel in 41 patients with non-resectable III and IV stage melanoma (50% in M1c 
stage). Nab-paklitaxel is composed of paklitaxel and albumin. This combination alleviates 
the adverse events caused by administration of paklitaxel alone. The percent of 6 and 12-
months survival was 91 and 83%, while the median OS was not reached (Boasberg et al., 
2009). The preliminary results of a phase II trial evaluating the efficacy of bevacizumab in 
combination with everolimus in first line treatment of advanced melanoma were presented 
at ASCO 2009 conference. Fifty six patients were qualified to the study, but the preliminary 
analysis included  31 subjects. PR was observed in 1 patient, SD in 19 patients and the 
median PFS was 3.5 months. The most frequent adverse event was mucositis. Grade 3 
toxicity was observed in 13% of patients, other grade 3 adverse events were noted in less 
than 10% of subjects (Peyton et al., 2009). 
αv integrin family such as αvb3 and αvb5  are related to the promotion of angiogenesis in the 
tumor and contribute to its growth. Human mAb CNTO 95 (intetumumab) directed against 
integrin has been found to show anticancer and antiangiogenic activity in animal models 
(Trikha et al., 2004). At the ASCO 2009 annual meeting results of the phase II trial with 129 
metastatic melanoma patients enrolled, were reported.  The patients were randomised into 
four study arms: (i) intetumumab 5 mg/kg; (ii) intetumumab 10 mg/kg; (iii) intetumumab 
10 mg/kg + DTIC; (iv) placebo + DTIC. Median OS of patients respectively in the above-
mentioned groups was 9.8; 14; 10.9 and 7.6 months. The treatment was well tolerated and 
the percent of patients with serious adverse events was the highest in the arm treated with 
dacarbazine (DTIC)  plus placebo (Loquai et al., 2009). Volociximab is a chimeric monoclonal 
antibody that combines with α5β1 integrin, inhibiting angiogenesis in tumors by damaging 
the bonds between endothelial cells and fibronectin in the intracellular cytoplasm. 
Effectiveness of volociksimab was evaluated in a phase II trial which enrolled 19 patients 
diagnosed with advanced melanoma after progression during the first line treatment. 
Objective clinical responses were observed only in 5% of the patients. Responses to the 
treatment were associated with the expression of integrin α5β1 in patients tumor 
samples.The treatment was relatively well tolerated. Grade 1 and 2 toxicity (nausea, 
vomiting, diarrhoea) occurred in 68% of patients (Linette et al., 2008).  
Overexpression of glycoprotein NMB (GPNMB) was observed in many malignancies 
including melanoma. CRO11-vcMMAE is a human mAb targeting extracellular domain of 
www.intechopen.com
 
Current Management of Malignant Melanoma 
 
100 
GPNMB, combined with the tubulin destabilising factor – monomethyl auristatin E 
(MMAE). The whole complex is stable in the blood, while MMAE is released within the 
tumour (Tse et al., 2006). CRO11-vcMMAE was evaluated in phase I/II clinical trials. At 
ASCO 2009 the phase II study results were reported (MTD 1.88 mg/kg); this trial enrolled 36 
patients with metastatic melanoma treated earlier with systemic therapy.  4 PR and 19 SD 
were observed, while the median PFS was 4 months. The most often noted grade 3 and 4 
included neutropenia (22% patients) and rash (19%). Rash grade 2 and higher correlated 
with longer PFS (Hwu et al., 2009). 
Another therapeutic strategy of specific immunotherapy is the use of TIL cells which are 
extracted from patients tumors and incubated ex vivo in the presence of IL-2. Next they are 
transferred back into corresponding patients with a simultaneous administration of IL-2. In 
1994, et al. observed objective clinical responses in 34% of patients with metastatic 
melanoma (Rosenberg et al., 1994b). However, therapeutic benefit was assigned to i.v. 
injected IL-2 which stimulated lymphocytes.  
To increase the efficacy of adoptive cell therapy, prior to TIL infusion, chemotherapy and/or 
total body irradiation (in order to obtain limfodepletion – elimination of suppressor T-cells) 
followed by administration of IL-2 was applied. Although effectiveness of this strategy was 
limited in the treatment of leukemia (Curti et al., 1998; Schultze et al., 2001) some activity in 
the therapy of melanoma was observed (Oble et al., 2009). Patients with metastatic 
melanoma prior to TIL and IL-2 infusion received a limphodepleting dose of 
cyclophosphamide and fludarabine (Dudley et al., 2005). In 51% (n=35) of treated patients 
objective response rate was observed. A very high overall response rate (70%) was seen in 
another trial where in melanoma patients prior to TIL transfusion a total body irradiation 
with a dose of 1200 cGy (in 3 fractionated doses) was obtained (Rosenberg et al., 2008).  
Clinical trials, which tested peripheral blood lymphocytes stimulated with cytokines did not 
produce the desired result due to low numbers of antigen-specific lymphocytes. In order to 
increase the number of antigen-specific lymphocytes an in vitro stimulation with DC loaded 
with particular antigen can be obtained. In a phase I study patients with metastatic 
melanoma were treated with CD8+ T cell isolated from peripheral blood and incubated ex 
vivo with mature autologous DC pulsed with melanoma antigen Melan-A. Objective 
responses were seen in 3 out of all 11 patients. (Mackensen et al., 2006).  It has been proven 
that administration of CD4+ T-cells instead of CD8+ lymphocytes may turn out to be more 
effective in adoptive cell therapy (Perez-Diez et al., 2002). Remission was observed in a 
patient with metastatic melanoma who received autologous CD4 + T cells specific for the 
melanoma antigen NY-ESO-1 (Hunder et al., 2008). 
Morgan et al. isolated PBLs which were then modified ex vivo with genes coding for TCR 
specific for a number of tumour-associated antigens (MART-1, gp100, NY-ESO-1 or p53). 
They demonstrated that modified PBLs recognise, in the context of HLA-A2, the above-
mentioned tumour antigens present on melanoma, lung and breast cancer cells. The 
interaction of TCR and tumour peptides was associated with the production of a large 
quantity of IFN-gamma. In the clinical trial, Morgan et al. enrolled 31 patients with 
advanced melanoma resistant to IL-2 therapy. All subjects received autologous PBLs 
engineered with the anti-MART-1 TCR gene. Two patients showed a prolonged remission 
lasting more than 20 months. Patients who achieved a clinical response also exhibited high 
levels of modified circulating lymphocytes after 1 year from the injection of transduced 
PBLs. No toxicity was found to be associated with this type of therapy (Morgan et al., 2006). 
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3.3 Active non-specific immunotherapy 
Active non-specific immunotherapy is a therapeutic method based on stimulation of the 
immune system, cell-mediated immune response in particular, with antigens that are not 
present in tumour cells. Historically, the therapy has involved microorganisms, microbial 
fragments, enzymes and hormones. In recent years, due to the development of advanced 
genetic engineering technology and growing understanding of immune mechanisms 
involved in tumour growth, immune response-modulating mAbs were constructed. 
Substances which contribute to the stimulation of immune processes include non-specific 
immunostimulators and immunomodulators. Immunostimulators include (i) intact 
microorganisms (living BCG – Bacillus Calmette-Guérin, killed Corynebacterium parvum),  
(ii) cell wall elements (BCG, Nocardia), (iii) microbial glycoproteins derived from Klebsiella, 
(iv) synthetic components, e.g. endotoxins (lipopolysaccharides). Immunomodulators 
include (i) thymus extracts (TPI, THF, TFX), (ii) synthetic thymus hormones (thymosin 
alpha-1, thymopoietin), (iii) tuftsin, (iv) enkephalins and endorphins (v) lymphocyte extracts 
(transfer factor, immunogenic RNA) (Hersh et al., 1991). 
Some of the substances listed above, when injected directly into the tumour, have triggered 
local inflammatory reaction associated with the infiltration of APCs, neutrophils, and T and 
B lymphocytes. Regression of injected tumours was often accomplished, however, the 
method was not capable of producing a specific systemic anti-tumour responses.  
No active non-specific immunotherapy modality has entered routine clinical practice as yet.  
Passive non-specific immunotherapy includes also monoclonal antibodies modulating the 
immune system. CTLA-4 is an immune checkpoint molecule that is up-regulated on 
activated T-cells, which suppresses further activation of specific CD4+ and CD8+ T-cells by 
interaction with DC or directly as a result of a contact between suppressor and effector T 
lymphocytes. The anti-CTLA4 monoclonal antibody by blocking the interaction of CTLA-4 
with CD80/86 switches off the mechanism of immune suppression and enables continous, 
unrestrained stimulation of T-cells by DC (J. Mackiewicz & Kwinta, 2010). Two IgG 
monoclonal antibodies directed against CTLA-4 – ipilimumab and tremelimumab have been 
tested in number of clinical trials in patients with melanoma. In 2011 (March) ipilimumab 
(Yervoy®) has been approved by FDA for the treatment of metastatic melanoma patients 
that failed previous systemic therapy. The approval was based on the results of a 
randomized phase III trial which included 676 HLA-A*0201–positive patients with 
unresectable stage III or IV melanoma. Patients enrolled were treated previously with IL-2 
or chemotherapy and were randomly assigned for administration of ipilimumab plus 
glycoprotein (gp)100 vaccine (403 patients), ipilimumab alone (137), or gp100 alone (136). 
Ipilimumab, at a dose of 3 mg per kilogram of body weight, was administered with or 
without gp100 every 3 weeks for up to four treatments. Patients receiving ipilimumab plus a 
peptide vaccine had a median survival of 10 months, compared with 6.4 months of patients 
receiving the gp100 alone (P<0.001). Subjects treated with ipilimumab alone had a nearly 
identical median survival — 10.1 months — in the 3-group clinical trial (P < 0.003). Immune 
related adverse events (grade 3 and 4) occurred in 10-15% of patients treated with 
ipilimumab and in 3% treated with gp100 alone (Hodi et al., 2010) 
Another monoclonal antibody targeting CTLA-4 is tremelimumab (administered in the dose 
of 15 mg/kg every 3 months), which effectiveness has been evaluated in a phase II trial in 
previously treated patients. From among 256 patients with metastatic melanoma enrolled 
into the study, objective clinical responses were observed in 8.3% patients, while the median 
OS was 10.2 months (Kirkwood et al., 2008). The above results inclined the next phase III 
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trial in which 643 patients were treated with tremelimumab in monotherapy or in 
combination with DTIC/TMZ in the first line setting. Analysis of preliminary results did not 
show the advantage of tremelimumab over the standard therapy (OS 11.8 vs 10.7) and the 
trial was terminated (Ribas et al., 2008). The effectiveness of treatment with tremelimumab in 
combination with high doses interferon-alfa-2b was evaluated in phase II trial in which from 
among 16 patients with inoperable stage III and IV melanoma, clinical response was 
observed in 19%.  The most frequent grade 3 and 4 adverse events included: neutropenia (3 
patients, 19%), elevated level of the liver enzymes (2, 13%), fatigue (6, 38%), anxiety (2, 13%) 
(Tarhini et al., 2008).  
Another human mAb modulating the immune system is MDX-1106 (Medarex) directed 
against PD-1 (a molecule close to that of CTLA-4), which undergoes expression on activated 
T lymphocytes. Results of the phase I trial have shown regression of the tumours in patients 
with advanced melanoma and low toxicity of the treatment (Brahmer et al., 2008).  
The monoclonal antibody BMS-663513 targeting co-stimulating molecule CD137 (4-1BB) acts 
according to a different mechanism. Binding of the ligand or anti-CD137 antibody with  
4-1BB receptor on the surface of T lymphocytes provides a co-stimulating signal enhancing 
the cell’s activation and triggering its proliferation. The phase I trial enrolling 54 patients 
with solid tumors has shown acceptable toxicity level and a certain clinical activity of  
BMS-663513 (Sznol et al., 2008). We look forward to the results of large randomised phase II 
study which has just been completed (US National Institutes of Health [NIH], 2008a).  
CP-870.893 is a human agonistic mAb against co-stimulating molecule CD40 that is  
up-regulated on the surface of the APC. Phase I trial has shown PR in 4 (27%) out of 15 
patients with advanced melanoma and 1 CR lasting 18 months after single administration of 
the drug (Vonderheide et al., 2006). Currently, the trial evaluating the efficacy of CP-870,893 
in combination with carboplatin and paclitaxel has been completed and the results probably 
will be disclosed soon (US National Institutes of Health [NIH], 2008b). 
3.4 Active specific immunotherapy 
Active specific immunotherapy is a method of treatment which stimulates immune response 
to antigens specific for a given tumour type. 
Active specific immunotherapy includes therapeutic cancer vaccines which encompass cell 
and non-cell based products. Cell based vaccines comprise: cancer cell lysates, whole cancer 
cells with adjuvants, gene modified whole cancer cells, DCs pulsed with DNA, RNA, 
peptides, proteins or cell lysates, pulsed DCs modified with immune stimulators, fused 
cancer cells with DCs cells or B-lymphocytes. Non-cell based vaccines include DNA vaccines 
(naked, plasmid), peptide vaccines, protein vaccines, viral-vector vaccines, anti-idiotypic 
antibody vaccines, particle based vaccines (Table 1) (J. Mackiewicz & A. Mackiewicz, 2009). 
3.4.1 Therapeutic cancer vaccines 
As early as in 1883, a New York surgeon William Colley was the first to make an attempt at 
administering a cancer vaccine. Colley injected bacterial toxins into sarcoma patients and 
observed disease remission. 
First-generation cancer vaccines were created from irradiated autologous or allogeneic 
tumour cells. Cell lysates or natural cell-surface tumour antigens (such as gangliosides GD-2 
and GM-2) were also used. In first-generation vaccines, injected cells or antigens were 
phagocytosed and degraded by mononuclear cells which are then presented to T and B 
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lymphocytes in the context of MHC molecules class I and II. Second generation vaccines 
include gene-modified tumour vaccines (GMTV) which use (autologous, allogeneic or 
mixed) tumour cells modified with genes encoding tumour antigens, immunostimulating 
factors, e.g. cytokines. Their functions include supply and presentation of tumour antigens 
together with providing co-stimulatory signal for the stimulation of specific anti-tumour 
mechanisms.  
 
Vaccine type Vaccine Reference 
Glycoprotein 100 (gp100)/tyrosinase complex 
with Incomplete Freund Adjuvant (IFA) and 
granulocyte macrophage colony-stimulating 
factor (GM-SCF) 
Weber et al., 2003 
Melanoma specific peptide (MART-1) + 
Incomplete Freund Adjuvant (IFA) 
Wang et al., 2003 
Peptide 
Melanoma specific peptide MAGE-A3 
Goldman & 
DeFrancesco 2009 
Heat Shock 
Protein (HSP) 
Autologous, tumor-derived heat-shock protein 
peptide complex glicoprotein96 + granulocyte 
macrophage colony-stimulating factor  
(GM-CSF)+ineterferon-alfa 
Pilla et al., 2006 
DNA coding epitopes of melanoma antigens: 
MELAN-A/MART-1 
Weber et al., 2008 
DNA 
DNA coding co-stimulating molecule – B7 Fynan et al., 1993 
Viral vector 
Vaccinia virus expressing three costimulatory 
molecules, B7.1, ICAM-1, and LFA-3  
(rV-TRICOM) 
Kaufman et al., 
2006 
Anti-idiotipic 
antibody 
BEC2 anti-idiotypic monoclonal antibody 
vaccine that mimics GD3 ganglioside 
Chapman et al., 
2004 
Tabele 1. Selected clinical non-cellular based vaccine studies in patients with melanoma 
The strategy of immunisation with genetically unmodified autologous DCs is based on ex 
vivo preincubation of DCs with tumour antigens, followed by administration to patients. 
This type of immunotherapy activates an antigen-specific cell-mediated response. 
3.4.1.1 Non-modified cell vaccines 
Vaccines based on whole tumour cells and stimulating factors (adjuvants) were one of the 
first and fundamental specific tumour immunotherapy strategies. Berd et al. (1990) 
evaluated the effects of immunisation of forty late-stage melanoma patients with a vaccine 
consisting of irradiated autologous melanoma cells mixed with BCG. Objective clinical 
response was observed in 5 patients, whereas median survival time was 10 months. The 
next stage was the use of established cell lines (allogeneic vaccines) which present antigens 
specific for a given tumour type. Their immunogenicity was enhanced by response to 
alloantigens present on vaccine cells. Allogeneic vaccines have superseded autologous 
vaccines due to the difficulties in obtaining the sufficient number of cells for repeated 
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vaccinations. A vaccine consisting of three established allogeneic melanoma lines 
(Cancervax®) and BCG as an adjuvant was developed by Morton et al. (1992). The ensuing 
phase II trial involved 157 advanced melanoma patients. Objective clinical response was 
observed in 15-20% of trial subjects (Chan et al., 1998). On the other hand, the outcome of 
randomised phase III clinical trials of patients treated with Cancervax failed to confirm 
prolonged survival of patients in comparison with the control group which received only 
BCG (Morton et al., 2007). 
Melacine is a melanoma tumor cell lysate vaccine consisting of two allogeneic melanoma 
cell lines (MSM-M-1 and MSM-M-2) combined with Detox® adjuvant (Vaishampayan et al., 
2002). After encouraging early phase studies the vaccine failed the phase III trial. Though, 
retrospective analysis showed that patients receiving Melacine and expressing at least two 
of five HLA antigens present on the vaccine cells developed longer RFS and OS (p =.0.0002 
and p = 0.0001, respectively). For that reason, the HLA pattern of the patient served here as 
a biomarker and allowed stratification of patients who would respond to the treatment. The 
Melacine may serve as an example of personalized therapeutic vaccine (J. Mackiewicz & A. 
Mackiewicz, 2010). 
Wallach et al in a multicenter randomized phase III trial assessed the efficacy of VMO – 
Vaccinia Melanoma Oncolysate. This preparation is a melanoma cell lysate (four cell lines) 
derived by infection of these lines by the vaccinia virus. The study enrolled 217 patients 
after resection of metastases to the lymph nodes. Test results showed no significant 
differences in RFS and OS (Wallack et al., 1998). 
3.4.1.2 Intracellular gene transfer 
Systems of intracellular gene transfer can be broadly divided into non-viral (physical) and 
viral. The former category includes (i) electroporation (mechanical introduction of DNA in 
the electric field), (ii) “gene gun” (injection of DNA-coated gold beads into cells by means of 
pressurised helium). Non-viral chemical strategies are based on modifications of cell 
membrane permeability for macromolecules under the influence of cationic compounds or 
enabling penetration of liposome-encapsulated genes marked by high affinity to cell 
membranes. The most common gene transfer systems used in genetic therapy of human 
cancer nowadays are based on viral vectors: retroviral, adenoviral, adeno-associated viruses 
(AAV)) and lentiviral. 
Recombinant retroviruses are predominantly based on Moloney murine leukaemia virus 
(MoMLV). They are used to transduce cells both in vitro and in vivo. Retroviruses transfer 
genetic material to dividing cells, with viral DNA becoming permanently incorporated into 
the host’s genome, thus producing constant expression of the therapeutic gene in target cells 
and their descendants. Retroviruses are vectors of choice for constructing cellular cancer 
vaccines. When administered in vivo to humans, murine-enveloped retroviruses are quickly 
eliminated via complement activation. Consequently, human vectors or human-enveloped 
vectors were constructed.   
Adenoviral vectors are used to modify tumour cells in vivo. A typical feature of adenoviral 
vectors is highly efficient transduction of target cells. On the other hand, as there is no 
interaction of genetic material with the host’s genome, gene expression is trasient. In the 
case of serial administration of adenoviral vectors, they are eliminated from the human 
body due to the presence of specific adenoviral antibodies in the human serum. The main 
feature distinguishing adenoviral carriers from retroviral vectors is the ability to deliver 
genes into non-dividing cells. Adeno-associated vectors (AAV) have a low capacity and an 
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ability of episomal (extrachromosomal) replication of genetic material and simultaneous 
integration of inserted genetic material with the host cell’s DNA. Initially, AAV vectors 
contained ”contaminants” in the form of immunogenic adenoviral particles necessary for 
AAV packaging, however new techniques have recently been developed to purify AAV 
vectors. 
Lentiviral vectors are based on the human immunodeficiency virus type 1 (HIV-1). They 
have a capacity of permanent integration of genetic material with dividing and non-dividing 
cell genomes and are thus an efficient tools used to transduce early CD34+ stem cells 
(approximately 40%). 
3.4.1.3 Genetically modified cell vaccines 
Rapid development of genetic engineering and gene transfer systems, combined with 
increasing knowledge of tumour immunology, have triggered a dynamic development of 
 
Immunostimulating 
factor 
Dominant type of anti-tumour effect 
IL-2 Direct anti-tumour effect 
Stimulation and proliferation of CD8+ lymphocytes and NK cells 
IFN-gamma Direct anti-tumour effect 
Stimulation of macrophages, induction of immune response, 
stimulation of expression of MHC and B7 cells 
Induction of chemokines which suppress neo-angiogenesis: IP-10, MIG 
IL-12 Secreted by DCs, powerfully stimulates CD4+, CD8+ and NK cells. 
Secondary secretion of IFN-gamma and polarisation towards  Th1-
type response 
IL-18 Secondary secretion of IFN-gamma and polarisation towards  Th1-
type response 
Suppressed secretion of IL-10 by stimulated T lymphocytes 
Stimulation of cytotoxic activity of NK cells by the Fas ligand 
GM-CSF Differentiation and maturation of DCs 
Stimulation of expression of MHC proteins, tumour antigens and co-
stimulatory cells in antigen-presenting cells 
IL-4 Tumour infiltration by macrophages and eosinophils 
Differentiation and maturation of DCs 
Stimulation of CD4+ cells 
TNF Direct anti-tumour effect (cytotoxic effect) 
Stimulation of specific and non-specific cell-mediated and humoral 
response 
IL-7 Stimulation of CD4+ and CD8+ cells 
IL-6+sIL6R Stimulation of CD4+, CD8+ and NK cells, DCs maturation, 
presentation of cryptic antigens by DCs, inhibition of Treg formation, 
induction of GM-CSF secretion by lymphocytes 
B7 Co-stimulatory signal for T cells 
HLA-B7 As an allogeneic HLA molecule – stimulation of local production of 
interferons and cytokines in the tumour microenvironment 
Table 2. Factors stimulating anti-tumour immune response used in genetic cancer therapy 
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gene-modified tumour cell vaccines (GMTV). GMTV vaccines are based on whole tumour 
cells that can be modified with genes encoding (i) immunostimulatory cytokines (such as IL-
2, IL-4, IL-6, IL-7, IL-12, IFN-gamma, TNF) (Table 2), (ii) costimulatory molecules (CD80, 
CD86), (iii) adhesion molecules, (iv) histocompatibility (MHC) antigens. The aim of genetic 
modification of cancer cells is to augment their immunogenicity, e.g. via phenotype 
modifications (increased expression of MHC I and II) or activation of effector mechanisms of 
the immune system via the delivery of costimulatory signals (J. Mackiewicz & A. Mackiewicz, 
2010). GMTV have been tested in many early phase clinical trials in the adjuvant and 
therapeutic settings (Table 3). 
 
Type of 
modified 
cells 
Vector Gene 
Trial 
phase 
Number of 
patients 
Clinical response
(stable disease) 
[mixed disease] 
Author and 
publication 
Autologous Liposomes HLA-B7 I 5 1 Nabel GJ et al., 1993 
Autologous Retrovirus IL-7 I 10 0 (4) [2] Moller et al., 1998 
Autologous Gene gun IL-12 I 6 0 (3) Sun Y et al., 1998 
Autologous Retrovirus GM-CSF I 29 0 Soiffer et al., 1998 
Autologous Retrovirus GM-CSF I 35  Soiffer et al., 2003 
Autologous Retrovirus IL-2 II 12 (3) Palmer et al., 1999 
Allogeneic ? IL-2 I 12 [3] Arienti et al., 1996 
Allogeneic ? IL-4 I 12 [2] Arienti et al., 1999 
Allogeneic ? IL-2 I/II 33 2 (7) Osanto et al., 2000 
Table 3. Results of gene therapy in metastatic melanoma – phase I/II trials 
Mackiewicz et al. at the European Society of Medical Oncology (ESMO) meeting 2010 
presented results of two phase II clinical trials conducted in almost 200 patients after 
resection of stage III and IV melanoma. In both studies patients were vaccinated with AGI-
101 composed of two irradiated melanoma cell lines modified to express Hyper-IL-6 – a 
fusion protein composed of interleukin 6 (IL-6) and soluble IL-6 receptor . AGI-101 (5 x 107 
cells per dose) was administered 8 times at 2-week intervals (induction phase) and then 
monthly (maintenance phase). At disease progression the induction phase (+/- surgery) was 
restarted, followed by a second maintenance phase. At progression 43 (Trial 3) and 39 (Trial 
5) patients were re-induced +/- surgery followed by a second maintenance phase; of those 
11 and 16 patients respectively are alive following re-induction. The 5-year survival in Trial 
3 was 66,7%, 43,8% and 26,1% respectively in stage IIIB, IIIC and IV. In Trial 5 the  5-year 
survival was as follows  56,3%, 39,8% and 41,2% correspondingly in stage IIIA/B, IIIC and 
IV. The OS observed in trial 3 was 4,4 years and 3,1 year in trial 5 (A. Mackiewicz et al., 
2010). The vaccine was well tolerated as no vaccine related toxicity of CTC>2 was detected. 
Intensive research of melanoma vaccines is currently curried out in a number of countries 
worldwide. However, no vaccine, has been approved by regulatory authorities so far. 
3.4.1.4 Vaccines based on dendritic cells  
Extensive research of DCs has shown that they are the most efficient APCs (Banchereau et 
al., 1998; Hart et al., 1997). DCs play a vital role in inducing immune response. They are the 
only representatives of APCs that are capable of inducing primary response of virgin T 
lymphocytes. The use of DCs for antigen presentation offers an opportunity to trigger 
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immune response even to weakly immunogenic tumour antigens and break immune 
tolerance.  
Human DCs are generated by isolation of immature DCs from blood (Fong et al., 2000) and 
differentiation ex vivo in the presence of IL-4 and GM-CSF, myeloid progenitor cells (CD34 
+) or monocytes (CD14 +) (Sallusto et al., 1994). Obtained immature DCs can be pulsed with 
tumor cell lysates (Nair SK et al. 1997) or synthetic peptides (Gitlitz et al., 2003), modified 
with genes encoding tumor antigens or tumor cells RNA (Ashley et al., 1997). For 
immunization are also used hybrids of DCs with tumor cells (Avigan et al., 2004). 
In a small trial, a group of 11 patients with advanced-stage melanoma were immunised with 
autologous DCs previously incubated with the MAGE-3 peptide presented by HLA-A1. 
Regression of cancerous lesions in the skin, lungs and the liver was achieved in 6 cases 
(Thurner et al., 1999). In one of the few randomized phase III studies, Schadendorf et al 
injected metastatic melanoma patients with autologous DC pulsed with peptides presented 
in the context of HLA class I and II. However, preliminary analysis has not demonstrated 
superiority of vaccine over dacarbazine (control arm) and the study was terminated 
(Schadendorf et al., 2006). Nevertheless, only 53 patients in the vaccine group and 55 in the 
control arm were participating in the trial and the vaccine was administered depending on 
the amount of DC cells, usually only from two to several times. Though, subsequent 
analysis showed that immunized patients with HLA-A2 +/HLA-B44 haplotyp lived longer 
than those treated with dacarbazine (Engel-Noerregaard et al., 2009). 
Peptide-pulsed DCs have certain limitations as well, including (i) short period of antigen 
presentation, dependent on the half-life of the MHC-peptide complex, (ii) the fact that using 
a given peptide is only limited to patients with an appropriate MHC haplotype (Amoscato et 
al., 1998). It is believed that the strategy of modified DCs can be both more efficient and 
more universal. DCs can also be loaded with genes encoding tumour antigens, 
immunostimulatory factors or cytokines. Furthermore, DCs derived from different patients 
can be modified with the same genetic sequence (no need to match appropriate MHC 
haplotypes), while expression of a given introduced sequence is long-term. 
Metharom et al. immunised mice with dendritic cells transduced with the mTRP-2 gene 
(tumour antigen of B16 murine melanoma cells). Tumour regression was observed in 4 out 
of 7 mice (Metharom et al., 2001).  
In a phase I/II trial, melanoma patients were immunised with autologous DCs transduced 
with tumour-derived mRNA, which enables lymphocytes to present – beside shared 
melanoma antigens – a wide range of tumour antigens that are unique for a given patient, as 
well as previously unknown antigens. The trial showed that the vaccine is completely safe. 
Response of T lymphocytes against tumour antigens encoded by tumour-derived mRNA in 
vivo was observed in the majority of cases (Kyte et al., 2006). 
Melanoma DC vaccines tested to date, despite encouraging results noted in phase I and II 
trials, have not proven effective in phase III randomised trials. 
4. Cancer immunotherapy clinical trial design  
Results of many promising early-phase clinical studies evaluating the effectiveness of 
immunotherapy have not been confirmed in phase III trials. It is becoming clear that these 
failures could be related to the design of clinical trials (Finke et al., 2007). At present, clinical 
trials design of new therapeutic strategies including immunotherapy are based on criteria 
developed for cytotoxic drugs. However immunotheraputics, especially of active 
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immunotherapy have very different clinical characteristics, mechanism of action and 
toxicity prifile than chemotherapeutic agents. Accordingly, new clinical immunotherapy 
trial design paradigm was developed (Hoos, et al., 2007 ). Here we outline some  aspects 
which should be considered while designing clinical trials for the assessment of the 
effectiveness of immunotherapy. 
Patients qualified to earlier clinical trials evaluating the efficacy of immunotheraputics were 
in late stage of the disease often treated previously with chemo- or radiotherapy. However, 
the highest clinical benefit was observed in patients with minimal residual disease and such 
patient population should be considered as candidates for immunotherapy trials (mainly 
cancer vaccine trials). 
Clinical trial end points evaluating chemotherapeutic agents drugs may not be adequate for 
immunotherapy trials. The Response Evaluation Criteria in Solid Tumors (RECIST) in the 
assessment of objective clinical response to chemotherapy may not reflect the benefit from 
immunotherapy. The time points between tumor assessments in trials evaluating 
immunotherapeutics should be longer (in contrast to chemotherapy trials) giving time for 
the immune system to mount response to the treatment. In a recent phase II metastatic 
melanoma study, patients treated with AGI-101H (genetically modified melanoma vaccine 
secreting Hyper-IL-6) developed clinical response usually after 3-4 months of treatment. 
However, in many patients tumor shrinkage was observed after several months or even 
years following SD (Nawrocki & A. Mackiewicz, 2007, Nawrocki et al., 2000).  Nevertheless, 
in many studies assessed tumors tend to enlarge first due to infiltration of inflammatory 
cells and then shrink. Furthermore immunotherapy may fall to induce tumor decrease, but 
yet still be effective in slowing the rate of progression giving the patient benefit in OS. The 
cancer Vaccine Clinical Trial Working Group (CVCTWG) propose that patients after initial 
clinically not significant progression should not be excluded from the treatment and 
following tumor regression their response rate could be scored based on the largest tumor 
volume measured after the start of treatment, not necessarily from baseline tumor volume 
(Hoos et al., 2007). Based on the observations from phase II clinical trial evaluating earlier 
described ipilimumab in metastatic melanoma patients’ new guidelines for evaluation of 
immune-related response criteria (irRC) have been developed. In some patients treated with 
ipilimumab responses after initial increase in total tumor burden in the presence of new 
lesions were observed. Those patterns were associated with favorable survival. According to 
irRC: (i) new, nonmeasurable lesions do not define progression; (ii) new measurable lesions 
are not defined as progression but are incorporated into tumor burden; (iii) progression of 
the disease has to be confirmed by a repeat consecutive assessment no less than 4 weeks 
from the first documented date (Wolchok, 2009). 
OS is a “gold standard” used for efficacy evaluation of new drugs and is a primary end 
point of choice in phase III clinical studies. OS is a very good end point, but might be 
affected by subsequent therapies, is time consuming, and requires large samples of patients. 
In efficacy randomized phase II trials using adoptive component might be required. 
DFS and PFS used respectively in adjuvant and metastatic disease setting are acceptable 
surrogate primary end points which can shorten the time of randomized efficacy trials. 
However, definitions of DFS and PFS might not be consistent for immunotherapy trials. 
While as mentioned before patient’s immune system needs time to develop clinical activity 
and even patients after progression of disease still may benefit from treatment. In terms of 
classical DFS/PFS description patients with relapse or progression of the disease could be 
excluded from the trial to early. Modifications of these definitions have been proposed: 
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confirmation of progression after at least second tumor assessments; not taking into account 
early progression within a defined time-interval (eg, three month from the beginning of the 
treatment). In patients who developed early progression with subsequent response to study 
treatment, the time of DFS and PFS should be calculation from the first day of drug 
administration (Hoos et al., 2007). Moreover, in some malignancies like melanoma where 
there is no optional effective second line treatment, immunotherapy should be continued. 
In patients developing progression, changes in immunotherapy schedule (induction phase) 
or metastasectomy may need to be performed. In our own melanoma study patients treated 
with AGI-101H vaccine received induction phase (8 doses in 2 week interval), with 
subsequent maintenance phase (1 dose monthly). After developing progression induction 
phase schedule followed by maintenance was performed. We observed that patients 
undergoing re-induction benefit from the treatment (Nawrocki & A. Mackiewicz, 2007, A. 
Mackiewicz et al., 2010). Similar observation was seen in the ipilimumab phase III study 
conducted in metastatic melanoma patients. Ipilimumab was administered four times in 3 
week intervals (induction phase). Patients with SD for 3 months duration after week 12 or a 
confirmed PR or CR were offered reinduction after developing progression. Among 31 
patients given reinduction therapy with ipilimumab, a CR, PR or SD was achieved by 21 
patients. 
A properly designed immunotherapy clinical trial is very important, while these agents in 
contrast to chemical agents or small molecules like tyrosine kinases inhibitors might cure 
patients with immunogenic malignancies (eg. melanoma, renal cell carcinoma) even when 
the disease is disseminated. In a highly selected patient population with metastatic 
melanoma (270 patients) treated with IL-2, CR was observed in 6% with median duration of 
response over 59 months. PR was seen in 10% of IL-2 treated patients. Disease did not 
progress in any patient responding for more than 30 months (Atkins et al., 1993 & 1994).  
Another example is a study evaluating ipiliumumab in metastatic melanoma patients, 
where best overall response (CR+PR) rate of only 10.9% was observed. However 60.0% of 
patients developed an objective response for at least 2 years (26.5 to 44.2 months[ongoing]) 
(Hodi et al., 2010).  
5. Conclusions and further directions of the development 
Recent approval of DC based prostate cancer vaccine – Stipuleucel-T or immunostimultory 
antibody – Yervoy prove the potential of active immunotherapeutic approaches to treat 
cancer. Recent better understanding of immune tolerance mechanisms and their braking, 
development of vaccine design and the paradigm of immunotherapy clinical trials design 
will lead to the boosting of progress in the field of active cancer immunotherapy. Since 
examples already include melanoma, certainly immune targeting especially specific active 
immunotherapy approaches such as melanoma therapeutic vaccine will continue to be 
tested and finally successful. Most likely immunotherapy will need to be combined with 
other modalities such as for ex. small molecules, but certainly without support of the 
immune system elimination of cancer may not be possible.  
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